T790M
T790M · SaudiVarKB evidence summary derived from retained literature mentions.
8Variant mentions
8Publications
1Associated gene records
1Associated phenotype records
Associated gene records
Co-mentioned in the same publications| Gene | Identifier / context | Articles | Mentions |
|---|---|---|---|
| EGFR | HGNC:3236 | 8 | 8 |
Associated phenotype records
Co-mentioned in the same publications| Phenotype | Identifier / context | Articles | Mentions |
|---|---|---|---|
| lung cancer | — | 5 | 5 |
Associated population records
Co-mentioned in the same publicationsNo retained population associations.
Supporting publications
8 records- 2026Pyrimidine-Based Third-Generation Tyrosine Kinase Inhibitors: A Medicinal Chemistry Perspective.Current pharmaceutical design1 mentions
- 2025Epidermal growth factor receptors unveiled: a comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors.Journal of drug targeting1 mentions
- 2025Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy - a literature review.RSC advances1 mentions
- 2024Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.PloS one1 mentions
- 2021LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.Drug design, development and therapy1 mentions
- 2019Liquid chromatography-tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites.Royal Society open science1 mentions
- 2019Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling.RSC advances1 mentions
- 2018Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma.RSC advances1 mentions